Author

Michael Bennett 1

1 Medical Associates Research

ADHERENCE TO PRESCRIBED DOSES OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN THE PHASE 3 PEARL-II, PEARL-III, AND PEARL-IV TRIALS

David E. Bernstein, Rui Tato Marinho, Daniel E. Cohen, Fritz Bredeek, Ferenc Schneider, Gunnar Norkrans, Manuela Curescu, Michael Bennett, Marina Maevskaya, Jeffrey Fessel, Yan Luo, Jeffrey Enejosa

SAFETY COMPARISON OF 12- AND 24-WEEK TREATMENTS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS: RESULTS FROM TURQUOISE-II

Heiner Wedemeyer, Xavier Forns, Antonio Craxi, Paul Kwo, Stefan Bourgeois, Michael Bennett, Stephen Ryder, Dominique Larrey, David Mutimer, Sandra Lovell, Manal Abunimeh, Marcos Pedrosa, Roger Trinh

SUSTAINED VIROLOGIC RESPONSE 12 WEEKS POST-TREATMENT WITH ABT-450/RITONAVIR/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN (SAPPHIRE I AND II) IS INDEPENDENT OF PATIENT SUBGROUPS

Maurizia Brunetto, Mihály Makara, Holger Hinrichsen, John Hanson, Michael Bennett, Eric Lawitz, Junyuan Xiong, Eoin Coakley, Tolga Baykal, Guy Neff

SYMPTOMS AND CLINICAL PRESENTATION ARE NOT PREDICTIVE OF ESOPHAGEAL REFLUX BURDEN IN OBESE PATIENTS EVALUATED FOR BARIATRIC SURGERY

Paul Hobbs, Michael Bennett, C Prakash Gyawali

Item 1 - 4 / 4
1